{"674832":{"#nid":"674832","#data":{"type":"event","title":"PhD Proposal by Elisa Schrader Echeverri","body":[{"value":"\u003Cp\u003EElisa Schrader Echeverri\u003Cbr\u003EBME PhD Proposal Presentation\u003Cbr\u003E\u003Cbr\u003E\u003Cstrong\u003EDate\u003C\/strong\u003E: 2024-06-13\u003Cbr\u003E\u003Cstrong\u003ETime\u003C\/strong\u003E: 2:00pm - 4:00pm\u003Cbr\u003E\u003Cstrong\u003ELocation \/ Meeting Link\u003C\/strong\u003E: HSRB II N600 \/ \u003Ca href=\u0022https:\/\/emory.zoom.us\/j\/95198657704\u0022\u003Ehttps:\/\/emory.zoom.us\/j\/95198657704\u003C\/a\u003E\u003Cbr\u003E\u003Cbr\u003E\u003Cstrong\u003ECommittee Members:\u003C\/strong\u003E\u003Cbr\u003EJames E. Dahlman, PhD (Advisor); Wilbur A. Lam, MD, PhD; Felipe Quiroz, PhD, Hanjoong Jo, PhD; Brandon Dixon, PhD\u003Cbr\u003E\u003Cbr\u003E\u003Cbr\u003E\u003Cstrong\u003ETitle\u003C\/strong\u003E: Design and formulation optimization of Lipid Nanoparticles (LNPs) carrying mRNA to the pancreas and the heart\u003Cbr\u003E\u003Cbr\u003E\u003Cstrong\u003EAbstract:\u003C\/strong\u003E\u003Cbr\u003EAlthough lipid nanoparticles (LNPs) have clearly become a clinically significant way of delivering RNA therapies as seen with Alnylam\u2019s ONPATTRO\u00ae used for genetic liver diseases and through Moderna\u2019s SPIKEVAX\u00ae and Pfizer-BioNTech\u2019s COMIRNATY\u00ae, used for vaccination against COVID-19, their presence in the clinic is still very limited, with much room for development. One of the biggest challenges is finding systemic LNPs that can target non-liver organs such as the pancreas and the heart. These two organs are examples that have historically been hard to target and that are related to diseases that continue to be directly correlated to increasing mortality rates. Through my work, I propose to 1) use previously established screening systems to identify potential pancreas targeting LNPs and 2) explore different formulation methods and parameters to further optimize a previously identified heart-delivering particle and apply it to a clinically relevant atherosclerotic disease model. To do this I will apply different quantification methods such as flow cytometry, immunofluorescence histology and single-cell spatial imaging systems. This work will help build a basis for better understanding how LNP composition and formulation process can affect their performance in vivo to further streamline their clinical relevance growth.\u003C\/p\u003E","summary":"","format":"limited_html"}],"field_subtitle":"","field_summary":[{"value":"\u003Cp\u003EDesign and formulation optimization of Lipid Nanoparticles (LNPs) carrying mRNA to the pancreas and the heart\u003Cbr\u003E\u003Cbr\u003E\u0026nbsp;\u003C\/p\u003E","format":"limited_html"}],"field_summary_sentence":[{"value":"Design and formulation optimization of Lipid Nanoparticles (LNPs) carrying mRNA to the pancreas and the heart"}],"uid":"27707","created_gmt":"2024-05-21 16:08:15","changed_gmt":"2024-05-21 16:08:59","author":"Tatianna Richardson","boilerplate_text":"","field_publication":"","field_article_url":"","field_event_time":{"event_time_start":"2024-06-13T14:00:00-04:00","event_time_end":"2024-06-13T16:00:00-04:00","event_time_end_last":"2024-06-13T16:00:00-04:00","gmt_time_start":"2024-06-13 18:00:00","gmt_time_end":"2024-06-13 20:00:00","gmt_time_end_last":"2024-06-13 20:00:00","rrule":null,"timezone":"America\/New_York"},"location":"HSRB II N600 ","extras":[],"groups":[{"id":"221981","name":"Graduate Studies"}],"categories":[],"keywords":[{"id":"102851","name":"Phd proposal"}],"core_research_areas":[],"news_room_topics":[],"event_categories":[{"id":"1788","name":"Other\/Miscellaneous"}],"invited_audience":[{"id":"78771","name":"Public"}],"affiliations":[],"classification":[],"areas_of_expertise":[],"news_and_recent_appearances":[],"phone":[],"contact":[],"email":[],"slides":[],"orientation":[],"userdata":""}}}